Affiliation:
1. Infectious Disease Unit, Massachusetts General Hospital, Boston.
Abstract
The combination of zidovudine (AZT) and 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 (HIV-1) replication in vitro with AZT-sensitive and AZT-resistant clinical isolates and HIV-1IIIB. Synergy was determined by the median-effect principle and isobologram techniques. Cytotoxicity of the agents was not observed. Clinical trials are ongoing to define the combination's role in HIV-1 therapy.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference36 articles.
1. Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro;Baba M.;Antimicrob. Agents Chemother.,1987
2. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects;Boucher C. A. B.;J. Infect. Dis.,1992
3. Chou J. and T.-C. Chou. 1987. Dose-effect analysis with microcomputers: quantitation of ED50 LD50 synergism antagonism low-dose risk receptor-ligand binding and enzyme kinetics. A computer software for IBM-PC and manual. Biosoft Cambridge.
4. Chou T.-C. 1991. The median-effect principle and the combination index for the quantitation of synergism and antagonism p. 61-102. In T.-C. Chou and D. Rideout (ed.) Synergism and antagonism in chemotherapy. Academic Press Inc. New York.
5. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors;Chou T.;Adv. Enzyme Regul.,1984
Cited by
65 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献